Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis.

Hepburn S, Cairns DA, Jackson D, Craven RA, Riley B, Hutchinson M, Wood S, Smith MW, Thompson D, Banks RE.

Proteomics Clin Appl. 2015 Jun;9(5-6):507-21. doi: 10.1002/prca.201400079. Epub 2015 Feb 26.

2.

Biomarkers and response to bevacizumab--response.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Alexandre Z, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann J, Hall G, Jayson GC, Selby PJ, Banks RE.

Clin Cancer Res. 2014 Feb 15;20(4):1058. doi: 10.1158/1078-0432.CCR-13-3269. No abstract available.

3.

VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancer.

Aggelis V, Craven RA, Peng J, Harnden P, Schaffer L, Hernandez GE, Head SR, Maher ER, Tonge R, Selby PJ, Banks RE.

Int J Oncol. 2013 Nov;43(5):1368-76. doi: 10.3892/ijo.2013.2066. Epub 2013 Aug 21.

4.

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann JA, Hall G, Jayson GC, Selby PJ, Banks RE.

Clin Cancer Res. 2013 Sep 15;19(18):5227-39. doi: 10.1158/1078-0432.CCR-13-0489. Epub 2013 Aug 9.

5.

Proteomics and the search for biomarkers for renal cancer.

Craven RA, Vasudev NS, Banks RE.

Clin Biochem. 2013 Apr;46(6):456-65. doi: 10.1016/j.clinbiochem.2012.11.029. Epub 2012 Dec 7. Review.

PMID:
23228867
6.

Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue.

Thompson SM, Craven RA, Nirmalan NJ, Harnden P, Selby PJ, Banks RE.

Proteomics Clin Appl. 2013 Apr;7(3-4):241-51. doi: 10.1002/prca.201200086. Epub 2013 Mar 6. Review.

7.

Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: assessment of overall technical variability and the impact of block age.

Craven RA, Cairns DA, Zougman A, Harnden P, Selby PJ, Banks RE.

Proteomics Clin Appl. 2013 Apr;7(3-4):273-82. doi: 10.1002/prca.201200065. Epub 2013 Mar 6.

8.

Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma.

Taylor C, Craven RA, Harnden P, Selby PJ, Banks RE.

Int J Oncol. 2012 Oct;41(4):1229-40. doi: 10.3892/ijo.2012.1561. Epub 2012 Jul 20.

9.

Shotgun proteomics of human bile in hilar cholangiocarcinoma.

Farid SG, Craven RA, Peng J, Bonney GK, Perkins DN, Selby PJ, Rajendra Prasad K, Banks RE.

Proteomics. 2011 May;11(10):2134-8. doi: 10.1002/pmic.201000653. Epub 2011 Apr 18.

PMID:
21500345
10.

Upregulation of Hic-5 in glomerulosclerosis and its regulation of mesangial cell apoptosis.

Hornigold N, Craven RA, Keen JN, Johnson T, Banks RE, Mooney AF.

Kidney Int. 2010 Feb;77(4):329-38. doi: 10.1038/ki.2009.417. Epub 2009 Dec 9.

11.

Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.

Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE.

Clin Cancer Res. 2009 Dec 15;15(24):7582-7592.

12.

Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma.

Vasudev NS, Sim S, Cairns DA, Ferguson RE, Craven RA, Stanley A, Cartledge J, Thompson D, Selby PJ, Banks RE.

Br J Cancer. 2009 Oct 6;101(7):1175-82. doi: 10.1038/sj.bjc.6605250.

13.

Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model.

Aggelis V, Craven RA, Peng J, Harnden P, Cairns DA, Maher ER, Tonge R, Selby PJ, Banks RE.

Proteomics. 2009 Apr;9(8):2118-30. doi: 10.1002/pmic.200800756.

PMID:
19337990
14.

Laser capture microdissection for proteome analysis.

Craven RA, Banks RE.

Curr Protoc Protein Sci. 2003 May;Chapter 22:Unit 22.3. doi: 10.1002/0471140864.ps2203s31.

PMID:
18429244
15.

Understanding and managing renal cell carcinoma: can proteomic studies contribute to clinical practice?

Craven RA, Banks RE.

Contrib Nephrol. 2008;160:88-106. doi: 10.1159/000125936. Review.

PMID:
18401164
16.

Circulating markers of biliary malignancy: opportunities in proteomics?

Bonney GK, Craven RA, Prasad R, Melcher AF, Selby PJ, Banks RE.

Lancet Oncol. 2008 Feb;9(2):149-58. doi: 10.1016/S1470-2045(08)70027-5. Review.

PMID:
18237849
17.

Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.

Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE.

Clin Cancer Res. 2007 Dec 15;13(24):7370-9.

18.

Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma.

Rees-Unwin KS, Craven RA, Davenport E, Hanrahan S, Totty NF, Dring AM, Banks RE, J Morgan G, Davies FE.

Br J Haematol. 2007 Nov;139(4):559-67.

PMID:
17979943
19.

Key clinical issues in renal cancer: a challenge for proteomics.

Banks RE, Craven RA, Harnden P, Madaan S, Joyce A, Selby PJ.

World J Urol. 2007 Dec;25(6):537-56. Epub 2007 Aug 25. Review.

PMID:
17721703
20.
21.

Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma.

Craven RA, Hanrahan S, Totty N, Harnden P, Stanley AJ, Maher ER, Harris AL, Trimble WS, Selby PJ, Banks RE.

Proteomics. 2006 Jul;6(13):3880-93.

PMID:
16739133
22.

Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma.

Craven RA, Stanley AJ, Hanrahan S, Dods J, Unwin R, Totty N, Harnden P, Eardley I, Selby PJ, Banks RE.

Proteomics. 2006 May;6(9):2853-64.

PMID:
16596713
23.

Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.

Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N.

J Pain. 2005 Jun;6(6):392-9.

PMID:
15943961
24.

Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry.

Mears R, Craven RA, Hanrahan S, Totty N, Upton C, Young SL, Patel P, Selby PJ, Banks RE.

Proteomics. 2004 Dec;4(12):4019-31.

PMID:
15478216
25.

Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines.

Craven RA, Stanley AJ, Hanrahan S, Totty N, Jackson DP, Popescu R, Taylor A, Frey J, Selby PJ, Patel PM, Banks RE.

Proteomics. 2004 Dec;4(12):3998-4009.

PMID:
15449380
26.

Measuring survival rates from sudden cardiac arrest: the elusive definition.

Sayre MR, Travers AH, Daya M, Greene HL, Salive ME, Vijayaraghavan K, Craven RA, Groh WJ, Hallstrom AP; PAD Investigators.

Resuscitation. 2004 Jul;62(1):25-34.

PMID:
15246580
27.

Conducting research using the emergency exception from informed consent: the Public Access Defibrillation (PAD) Trial experience.

Mosesso VN Jr, Brown LH, Greene HL, Schmidt TA, Aufderheide TP, Sayre MR, Stephens SW, Travers A, Craven RA, Weisfeldt ML; PAD Trial Investigators.

Resuscitation. 2004 Apr;61(1):29-36.

PMID:
15081178
28.

Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect.

Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ, Banks RE.

Proteomics. 2003 Aug;3(8):1620-32.

PMID:
12923786
30.

Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma.

Unwin RD, Harnden P, Pappin D, Rahman D, Whelan P, Craven RA, Selby PJ, Banks RE.

Proteomics. 2003 Jan;3(1):45-55.

PMID:
12548633
31.

Use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis.

Craven RA, Banks RE.

Methods Enzymol. 2002;356:33-49. No abstract available.

PMID:
12418186
32.

Increased protein entry together with improved focussing using a combined IPGphor/Multiphor approach.

Craven RA, Jackson DH, Selby PJ, Banks RE.

Proteomics. 2002 Aug;2(8):1061-3. No abstract available.

PMID:
12203901
33.
34.

Laser capture microdissection and proteomics: possibilities and limitation.

Craven RA, Banks RE.

Proteomics. 2001 Oct;1(10):1200-4. Review.

PMID:
11721632
35.
36.

Use of bilevel positive airway pressure in out-of-hospital patients.

Craven RA, Singletary N, Bosken L, Sewell E, Payne M, Lipsey R.

Acad Emerg Med. 2000 Sep;7(9):1065-8.

37.

Vectors for the expression of tagged proteins in Schizosaccharomyces pombe.

Craven RA, Griffiths DJ, Sheldrick KS, Randall RE, Hagan IM, Carr AM.

Gene. 1998 Oct 9;221(1):59-68.

PMID:
9852950
38.

Molecular architecture of the ER translocase probed by chemical crosslinking of Sss1p to complementary fragments of Sec61p.

Wilkinson BM, Esnault Y, Craven RA, Skiba F, Fieschi J, K'epès F, Stirling CJ.

EMBO J. 1997 Aug 1;16(15):4549-59.

39.
40.
41.

Centralized off-premise transcription service: a model.

Craven RA.

J Emerg Med. 1995 Sep-Oct;13(5):697-702.

PMID:
8530795
42.

Dominant mutants identify new roles for p34cdc2 in mitosis.

Labib K, Craven RA, Crawford K, Nurse P.

EMBO J. 1995 May 15;14(10):2155-65.

43.

The materials management-financial administration partnership.

Lake H, Craven RA.

Hosp Purch Manage. 1983 Jul;8(7):15-7. No abstract available.

PMID:
10260889
44.
45.

Necrotizing papillitis.

CRAVEN RA.

Med J Aust. 1962 May 12;49(1):709-10. No abstract available.

PMID:
13882047

Supplemental Content

Loading ...
Support Center